A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related pathway

Chia-Lun Wu, Chun-Liang Chen, Hsu-Shan Huang, Dah-Shyong Yu

Research output: Contribution to journalArticle

Abstract

The incidence and mortality rate of urological cancers is increasing yearly. Niclosamide has been repurposed as an anti-cancer drug in recent years. Synthesized derivative of niclosamide was testified for its anti-cancer activity in urological cancers. MTT assay was used to measure the cytotoxicity effect of niclosamide and its derivatives in urological cancer cell lines. Migratory ability was monitored by scratch migration assay. Apoptosis and cell cycle changes were analyzed by annexin V and PI staining. The apoptosis-related signal proteins were evaluated by western blotting. T24 had the best drug sensitivity with the lowest IC50 in niclosamide and B17 treatment than DU145 and Caki-1 cells. After niclosamide and B17 treatment, the mitotic cells were decreased, but apoptotic bodies and morphology changes were not prominent in T24, Caki-1, and DU145 cells. The migratory ability was inhibited in niclosamide treatment than control group on Caki-1 cells and niclosamide and B17 treatment than control group on DU145 cells. Early apoptosis cells were increased after niclosamide and B17 treatment than control group without cell cycle changes in T24, Caki-1, and DU145 cells. Programmed cell death was activated majorly through PAPR and bcl-2 in T24 and caspase-3 in Caki-1 cells, respectively. Niclosamide and B17 derivative had good ability in inhibition proliferation and migratory ability in T24, Caki-1, and DU145 cells without prominent morphology and apoptotic body changes. UCC cells are more sensitive to niclosamide and B17 treatment. Early apoptosis was induced after niclosamide and B17 treatment through different mechanisms in T24, Caki-1, and DU145 cells.

Original languageEnglish
JournalCancer Medicine
DOIs
Publication statusE-pub ahead of print - Jun 28 2018

Fingerprint

Niclosamide
Urologic Neoplasms
Apoptosis
Growth
Control Groups
Cell Cycle
Annexin A5
Caspase 3
Pharmaceutical Preparations
Inhibitory Concentration 50

Cite this

A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related pathway. / Wu, Chia-Lun; Chen, Chun-Liang; Huang, Hsu-Shan; Yu, Dah-Shyong.

In: Cancer Medicine, 28.06.2018.

Research output: Contribution to journalArticle

@article{5877b5b7108a4630bc420784827a7e5b,
title = "A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related pathway",
abstract = "The incidence and mortality rate of urological cancers is increasing yearly. Niclosamide has been repurposed as an anti-cancer drug in recent years. Synthesized derivative of niclosamide was testified for its anti-cancer activity in urological cancers. MTT assay was used to measure the cytotoxicity effect of niclosamide and its derivatives in urological cancer cell lines. Migratory ability was monitored by scratch migration assay. Apoptosis and cell cycle changes were analyzed by annexin V and PI staining. The apoptosis-related signal proteins were evaluated by western blotting. T24 had the best drug sensitivity with the lowest IC50 in niclosamide and B17 treatment than DU145 and Caki-1 cells. After niclosamide and B17 treatment, the mitotic cells were decreased, but apoptotic bodies and morphology changes were not prominent in T24, Caki-1, and DU145 cells. The migratory ability was inhibited in niclosamide treatment than control group on Caki-1 cells and niclosamide and B17 treatment than control group on DU145 cells. Early apoptosis cells were increased after niclosamide and B17 treatment than control group without cell cycle changes in T24, Caki-1, and DU145 cells. Programmed cell death was activated majorly through PAPR and bcl-2 in T24 and caspase-3 in Caki-1 cells, respectively. Niclosamide and B17 derivative had good ability in inhibition proliferation and migratory ability in T24, Caki-1, and DU145 cells without prominent morphology and apoptotic body changes. UCC cells are more sensitive to niclosamide and B17 treatment. Early apoptosis was induced after niclosamide and B17 treatment through different mechanisms in T24, Caki-1, and DU145 cells.",
author = "Chia-Lun Wu and Chun-Liang Chen and Hsu-Shan Huang and Dah-Shyong Yu",
note = "{\circledC} 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2018",
month = "6",
day = "28",
doi = "10.1002/cam4.1635",
language = "English",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related pathway

AU - Wu, Chia-Lun

AU - Chen, Chun-Liang

AU - Huang, Hsu-Shan

AU - Yu, Dah-Shyong

N1 - © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

PY - 2018/6/28

Y1 - 2018/6/28

N2 - The incidence and mortality rate of urological cancers is increasing yearly. Niclosamide has been repurposed as an anti-cancer drug in recent years. Synthesized derivative of niclosamide was testified for its anti-cancer activity in urological cancers. MTT assay was used to measure the cytotoxicity effect of niclosamide and its derivatives in urological cancer cell lines. Migratory ability was monitored by scratch migration assay. Apoptosis and cell cycle changes were analyzed by annexin V and PI staining. The apoptosis-related signal proteins were evaluated by western blotting. T24 had the best drug sensitivity with the lowest IC50 in niclosamide and B17 treatment than DU145 and Caki-1 cells. After niclosamide and B17 treatment, the mitotic cells were decreased, but apoptotic bodies and morphology changes were not prominent in T24, Caki-1, and DU145 cells. The migratory ability was inhibited in niclosamide treatment than control group on Caki-1 cells and niclosamide and B17 treatment than control group on DU145 cells. Early apoptosis cells were increased after niclosamide and B17 treatment than control group without cell cycle changes in T24, Caki-1, and DU145 cells. Programmed cell death was activated majorly through PAPR and bcl-2 in T24 and caspase-3 in Caki-1 cells, respectively. Niclosamide and B17 derivative had good ability in inhibition proliferation and migratory ability in T24, Caki-1, and DU145 cells without prominent morphology and apoptotic body changes. UCC cells are more sensitive to niclosamide and B17 treatment. Early apoptosis was induced after niclosamide and B17 treatment through different mechanisms in T24, Caki-1, and DU145 cells.

AB - The incidence and mortality rate of urological cancers is increasing yearly. Niclosamide has been repurposed as an anti-cancer drug in recent years. Synthesized derivative of niclosamide was testified for its anti-cancer activity in urological cancers. MTT assay was used to measure the cytotoxicity effect of niclosamide and its derivatives in urological cancer cell lines. Migratory ability was monitored by scratch migration assay. Apoptosis and cell cycle changes were analyzed by annexin V and PI staining. The apoptosis-related signal proteins were evaluated by western blotting. T24 had the best drug sensitivity with the lowest IC50 in niclosamide and B17 treatment than DU145 and Caki-1 cells. After niclosamide and B17 treatment, the mitotic cells were decreased, but apoptotic bodies and morphology changes were not prominent in T24, Caki-1, and DU145 cells. The migratory ability was inhibited in niclosamide treatment than control group on Caki-1 cells and niclosamide and B17 treatment than control group on DU145 cells. Early apoptosis cells were increased after niclosamide and B17 treatment than control group without cell cycle changes in T24, Caki-1, and DU145 cells. Programmed cell death was activated majorly through PAPR and bcl-2 in T24 and caspase-3 in Caki-1 cells, respectively. Niclosamide and B17 derivative had good ability in inhibition proliferation and migratory ability in T24, Caki-1, and DU145 cells without prominent morphology and apoptotic body changes. UCC cells are more sensitive to niclosamide and B17 treatment. Early apoptosis was induced after niclosamide and B17 treatment through different mechanisms in T24, Caki-1, and DU145 cells.

U2 - 10.1002/cam4.1635

DO - 10.1002/cam4.1635

M3 - Article

C2 - 29953738

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -